Female contraception: Present and future perspectives

Current Women's Health Reviews

Volumn 5, Issue 3, 2009, Pages 167-175

  Rajesh, Naz ^a   Rowan, Shon ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Condom; Contraceptive vaccine; Female contraception; Intrauterine devices (IUDs); Pills

Indexed keywords

CONTRACEPTIVE VACCINE; ESTRADIOL; ETONOGESTREL; GESTAGEN; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; SEMEN VACCINE; SPERMICIDAL AGENT; UNCLASSIFIED DRUG; ZONA PELLUCIDA VACCINE;

ABSTINENCE; BARRIER CONTRACEPTION; COITUS; CONDOM; CONTRACEPTION; FAMILY PLANNING; FEMALE STERILIZATION; HORMONAL CONTRACEPTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; PILL; PREGNANCY; PRIORITY JOURNAL; REVIEW; TRANSDERMAL PATCH; UNITED STATES; UTERINE CERVIX CAP; UTERINE TUBE STERILIZATION; VAGINA RING;

EID: 74849127938     PISSN: 15734048     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340409789007259     Document Type: Review

References (81)

1. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006; 38: 90-6.
2. Kost K, Singh S, Vaughan B, Trussell J, Bankole A. Estimates of contraceptive failure from the 2002 National Survey of Family Growth. Contraception 2008; 77: 10-21.
3. Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. 7th ed. Philadelphia, PA: Lippincott Williams and Wilkins 2005.
4. Nakajima ST. Contemporary guide to contraception. 3rd ed. Newtown, PA: Handbooks in Health Care 2007.
5. Reape KZ. Current contraceptive research and development. Adolesc Med Clin 2005; 16: 617-33.
6. Chandra A, Martinez GM, Mosher WD, Abma JC, Jones J. Fertility, family planning, and reproductive health of U.S. women: Data from the 2002 National Survey of Family Growth. National Center for Health Statistics. Vital Health Stat 23 2005. Available from: http://www.cdc.gov/nchs/data/series/sr-23/sr23- 025.pdf
7. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179: 577-82.
8. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003; 68: 89-96.
9. Raymond EG. Progestin-only pills. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D. Contraceptive technology. 19th ed. New York, NY: Ardent Media 2007; pp. 181-92.
10. Rice CF, Killick SR, Dieben T, Coelingh Bennink H. A comparison of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel 30 micrograms daily. Hum Reprod 1999; 14: 982-5.
11. Moghissi KA, Syner FN, McBride LC. Contaceptive mechanism of microdose norethindrone. Obstet Gynecol 1971; 4: 585-94.
12. Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323: 1375-81.
13. Kjos SL, Peters RK, Xiang A, Thomas D, Schaefer U, Buchanan TA. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 1998; 280: 533-8.
14. Broome M, Fotherby K. Clinical experience with the progestogenonly pill. Contraception 1990; 42: 489-95.
15. Nelson JH. The use of the mini pill in private practice. J Reprod Med 1973; 10: 139-43.
16. Tayob Y, Adams J, Jacobs HS, Guillebaud J. Ultrasound demonstration of increased frequency of functional ovarian cysts in women using progestogen-only oral contraception. Br J Obstet Gynaecol 1985; 92: 1003-9.
17. Ortho Evra information. Available at: http://www.fda.gov/cder/ drug/infopage/orthoevra.
18. Abrams LS, Skee DM, Natarajan J, Wong FA, Anderson GD. Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites. Br J Clin Pharmacol 2002; 53: 141-6.
19. Trussell J. Contraceptive failure in the United States. Contraception 2004; 70: 89-96.
20. Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002; 77: 13-8.
21. Sibai BM, Odlind V, Meador ML, Shangold GA, Fisher AC, Creasy GW. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertil Steril 2002; 77: 19-26.
22. Archer DF, Bigrigg A, Smallwood GH, Shangold GA, Creasy GW, Fisher AC. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. Fertil Steril 2002; 77: 27-31.
23. Fraser IS, Weisberg E, Kumar N, et al. An initial pharmacokinetic study with a Metered Dose Transdermal Systemfor delivery of the progestogen Nestorone as a possible future contraceptive. Contraception 2007; 76: 432-8.
24. Mishell DR Jr, Talas M, Parlow AF, Moyer DL. Contraception by means of a silastic vaginal ring impregnated with medroxyprogesterone acetate. Am J Obstet Gynecol 1970; 107: 100-7.
25. NuvaRing full prescribing information: http://www.spfiles.com/ pinuvaring.pdf
26. Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000; 39: 233-42.
27. Sulak PJ, Smith V, Coffee A, Witt I, Kuehl AL, Kuehl TJ. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. Obstet Gynecol 2008; 112: 563-71.
28. Szarewski A. High acceptability and satisfaction with Nuvaring use. Eur J Contracept Reprod Health Care 2002; 7: 31-6.
29. Brucker C, Karck U, Merkle E. Cycle control, tolerability, efficacy and acceptability of the vaginal contraceptive ring, NuvaRing: results of clinical experience in Germany. Eur J Contracept Reprod Health Care 2008; 13: 31-8.
30. Oddsson K, Leifels-Fischer B, de Melo NR, et al. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 2005; 71: 176-82.
31. Ahrendt HJ, Nisand I, Bastianelli C, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception 2006; 74: 451-7.
32. Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 2001; 16: 469-75.
33. Depo Provera physician prescribing information: http://www.pfizer. com/files/products/uspi-depo-provera-contraceptive.pdf
34. Bassol S, Garza-Flores J, Cravioto MC, et al. Ovarian function following a single administration of depo-medroxyprogesterone acetate (DMPA) at different doses. Fertil Steril 1984; 42: 216-22.
35. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception 2004; 70: 269-75.
36. Smith RD, Cromer BA, Hayes JR, Brown RT. Medroxyprogesterone acetate (Depo-Provera) use in adolescents: uterine bleeding and blood pressure patterns, patient satisfaction, and continuation rates. Adolesc Pediatr Gynecol 1995; 8: 24-28.
37. Polaneczky M, Liblanc M. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents. J Adolesc Health 1998; 23: 81-8.
38. Harel Z, Biro FM, Kollar LM, Rauh JL. Adolescents' reasons for and experience after discontinuation of the long-acting contraceptives Depo-Provera and Norplant. J Adolesc Health 1996; 19: 118-23.
39. Cromer BA, Bonny AE, Stager M, et al. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study. Fertil Steril 2008; 90: 2060-7.
40. Sivin I, Nash H, Waldman S. Jadelle levonorgestrel rod implants: a summary of scientific data and lessons learned from programmatic experience (monograph on the internet). New York: Population Council; 2002 (cited 2009 Mar 5). Available from: http://www.popcouncil.org/pdfs/jadelle-monograph.pdf
41. Wenzl R, van Beek A, Schnabel P, Huber J. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon. Contraception 1998; 58: 283-8.
42. Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril 2009; 91(5): 164-53.
43. Mäkäräinen L, van Beek A, Tuomivaara L, Asplund B, Coelingh Bennink H. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril 1998; 69: 714-21.
44. MacIsaac L, Espey E. Intrauterine contraception: the pendulum swings back. Obstet Gynecol Clin North Am 2007; 34: 91-111.
45. Mirena (product monograph). Montville, NJ: Berlex Laboratories; 2003.
46. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994; 49: 56-72.
47. Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception 2007; 75: 16-30.
48. Stewart F, Trussell J, Van Look PFA. Emergency contraception. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D. Contraceptive technology. 19th ed. New York, NY: Ardent Media; 2007. p. 87-116.
49. Yuzpe AA, Lancee WJ. Ethinylestradiol and dl-norgestrel as a postcoital contraceptive. Fertil Steril 1977; 28: 932-6.
50. Trussell J, Rodríguez G, Ellertson C. Updated estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception 1999; 59: 147-51.
51. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1998; 352: 428-33.
52. Cheng L, Gülmezoglu AM, Piaggio G, Ezcurra E, Van Look PF. Interventions for emergency contraception. Cochrane Database Syst Rev 2008; CD001324.
53. MacKay AP, Kieke BA Jr, Koonin LM, Beattie K. Tubal sterilization in the United States, 1994-1996. Fam Plann Perspect 2001; 33: 161-5.
54. Peterson HB, Xia Z, Hughes JM, Wilcox LS, Tylor LR, Trussell J. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol 1996; 174: 1161-8.
55. Pollack AE, Thomas LJ, Barone MA. Female and male sterilization. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D. Contraceptive technology. 19th ed. New York, NY: Ardent Media; 2007; pp. 361-402.
56. Hillis SD, Marchbanks PA, Tylor LR, Peterson HB. Poststerilization regret: findings from the United States Collaborative Review of Sterilization. Obstet Gynecol 1999; 93: 889-95.
57. Kerin JF, Carignan CS, Cher D. The safety and effectiveness of a new hysteroscopic method for permanent birth control: results of the first Essure pbc clinical study. Aust N Z J Obstet Gynaecol 2001; 41: 364-70.
58. Syed R, Levy J, Childers ME. Pain associated with hysteroscopic sterilization. JSLS 2007; 11: 63-5.
59. Chandra A, Martinez GM, Mosher WD, Abma JC, Jones J. Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. Vital Health Stat 2005; 23: 1-160.
60. Warner L, Steiner MJ. Male condoms. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D. Contraceptive technology. 19th ed. New York, NY: Ardent Media; 2007; pp. 297-316.
61. Freziers RG, Walsh TL, Nelson AL, Clark VA, Coulson AH. Breakage and acceptability of a polyurethane condom: a randomized, controlled study. Fam Plann Perspect 1998; 30: 73-8.
62. Cates W, Raymond EG. Vaginal barriers and spermicides. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D. Contraceptive technology. 19th ed. New York, NY: Ardent Media; 2007; pp. 317-36.
63. Galvão LW, Oliveira LC, Díaz J, Kim DJ, Marchi N, van Dam J, et al. Effectiveness of female and male condoms in preventing exposure to semen during vaginal intercourse: a randomized trial. Contraception 2005; 71: 130-6.
64. Mauck CK, Weiner DH, Creinin MD, Archer DF, Schwartz JL, Pymar HC, et al. FemCap with removal strap: ease of removal, safety and acceptability. Contraception 2006; 73: 59-64.
65. Shihata AA, Gollub E. Acceptability of a new intravaginal barrier contraceptive device (Femcap). Contraception 1992; 46: 511-9.
66. Faich G, Pearson K, Fleming D, Sobel S, Anello C. Toxic shock syndrome and the vaginal contraceptive sponge. JAMA 1986; 255: 216-8.
67. Kuyoh MA, Toroitich-Ruto C, Grimes DA, Schulz KF, Gallo MF. Sponge versus diaphragm for contraception: a Cochrane review. Contraception 2003; 67: 15-8.
68. Roddy RE, Zekeng L, Ryan KA, Tamoufé U, Weir SS, Wong EL. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998; 339: 504-10.
69. Jain RK, Maikhuri JP, Kiran Kumar ST, Sharma VL, Dwivedi AK, Mitra K, et al. Novel disulphide esters of carbothioic acid as potent, non-detergent spermicides with low toxicity to Lactobacillus and HeLa cells in vitro. Hum Reprod 2007; 22: 708-16.
70. Jennings VH, Arevalo M. Fertility awareness-based methods. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D. Contraceptive technology. 19th ed. New York, NY: Ardent Media; 2007; pp. 343-60.
71. Arévalo M, Jennings V, Sinai I. Efficacy of a new method of family planning: the Standard Days Method. Contraception 2002; 65: 333-8.
72. Sinai I, Jennings V, Arévalo M. The Two Day Algorithm: a new algorithm to identify the fertile time of the menstrual cycle. Contraception 1999; 60: 65-70.
73. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-55.
74. Holt VL, Scholes D, Wicklund KG, Cushing-Haugen KL, Daling JR. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 2005; 105: 46-52.
75. Brunner Huber LR, Toth JL. Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth. Am J Epidemiol 2007; 166: 1306-11.
76. Zieman M, Guillebaud J, Weissberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002; 77: 13-8.
77. Huber LR, Huber KR. Contraceptive choices of women 35-44 years of age: findings from the behavioral risk factor surveillance system. Ann Epidemiol 2009; [Epub ahead of print].
78. Naz RK. Contraceptive vaccines. Drugs 2005; 65: 593-603.
79. Naz RK, Gupta SK, Gupta JC, Vyas HK, Talwar GP. Recent advances in contraceptive vaccine development: a mini-review. Hum Reprod 2005; 20: 3271-83.
80. Naz RK. Status of contraceptive vaccines. Am J Reprod Immunol 2008; 61: 11-18.
81. Talwar GP, Singh O, Pal R, et al. A vaccine that prevents pregnancy in women. Proc Natl Acad Sci USA 1994; 91: 8532-6.